MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

Search

Alkermes PLC

Suletud

SektorTervishoid

29.2 1.11

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

28.65

Max

29.5

Põhinäitajad

By Trading Economics

Sissetulek

-124M

22M

Müük

-123M

307M

P/E

Sektori keskmine

13.624

40.527

Aktsiakasum

0.291

Kasumimarginaal

7.329

Töötajad

1,800

EBITDA

-168M

14M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+38.65% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

23. juuli 2025

Turustatistika

By TradingEconomics

Turukapital

-1.1B

4.7B

Eelmine avamishind

28.09

Eelmine sulgemishind

29.2

Uudiste sentiment

By Acuity

50%

50%

143 / 375 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Alkermes PLC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. juuli 2025, 15:29 UTC

Suurimad hinnamuutused turgudel

Mustang Bio Shares Jump After Orphan Drug Designation for Cancer Treatment

7. juuli 2025, 23:44 UTC

Market Talk

Nikkei May Fall on U.S. Tariff Concerns -- Market Talk

7. juuli 2025, 23:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. juuli 2025, 23:41 UTC

Market Talk

Gold Edges Lower Amid Hopes for Possible Trade Agreements -- Market Talk

7. juuli 2025, 23:19 UTC

Market Talk

Global Equities Roundup: Market Talk

7. juuli 2025, 23:19 UTC

Market Talk

AML3D Bull Sees Navy Letter Lowering Risks -- Market Talk

7. juuli 2025, 22:20 UTC

Market Talk

Global Equities Roundup: Market Talk

7. juuli 2025, 22:20 UTC

Market Talk

AT&T's Fiber Strategy Positions Stock to Outperform -- Market Talk

7. juuli 2025, 21:34 UTC

Omandamised, ülevõtmised, äriostud

BlackRock's Latest Acquisition Is a Commercial Real Estate Bet -- Barrons.com

7. juuli 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

7. juuli 2025, 20:45 UTC

Omandamised, ülevõtmised, äriostud

CoreWeave Is Buying Core Scientific. The CEO Explains Why. -- Barrons.com

7. juuli 2025, 20:16 UTC

Market Talk

Canada Bonds Set to Benefit From Rotation Away U.S. Assets -- Market Talk

7. juuli 2025, 19:37 UTC

Market Talk

U.S. Natural Gas Futures Hold Their Ground -- Market Talk

7. juuli 2025, 19:12 UTC

Market Talk

Oil Futures Shrug Off Bigger OPEC+ Output Increase -- Market Talk

7. juuli 2025, 18:33 UTC

Market Talk

Gold Flat as Investors Assess Market Direction -- Market Talk

7. juuli 2025, 18:27 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. juuli 2025, 16:53 UTC

Tulu

Freight Stocks Have a Tariff Overhang. Morgan Stanley Says It Could Be Worse. -- Barrons.com

7. juuli 2025, 16:30 UTC

Market Talk

Higher Prices Limit Power Sector's Natural Gas Use -- Market Talk

7. juuli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7. juuli 2025, 16:05 UTC

Omandamised, ülevõtmised, äriostud

CoreWeave Is Buying Core Scientific. The CEO Explains Why. -- Barrons.com

7. juuli 2025, 15:41 UTC

Market Talk

Gold Futures Fall as Stronger U.S. Dollar Undermines Safe-Haven Demand -- Market Talk

7. juuli 2025, 15:41 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

7. juuli 2025, 15:40 UTC

Market Talk

Base Metal Prices Tick Lower on U.S. Dollar Strength -- Market Talk

7. juuli 2025, 15:30 UTC

Market Talk

Physical Oil Market Stable But Structural Weakness Looms -- Market Talk

7. juuli 2025, 15:18 UTC

Market Talk

BNP Cuts Brent Forecast on U.S. Shale, Iran Supply Resilience -- Market Talk

7. juuli 2025, 15:14 UTC

Omandamised, ülevõtmised, äriostud

MicroStrategy Goes a Week Without Buying Bitcoin. Saylor Has Advice for Crypto Traders. -- Barrons.com

7. juuli 2025, 15:00 UTC

Omandamised, ülevõtmised, äriostud

GSK Completes Acquisition of Efimosfermin

7. juuli 2025, 14:52 UTC

Market Talk

Dollar Faces Downward Pressures Stemming from Tariffs -- Market Talk

7. juuli 2025, 14:51 UTC

Market Talk

Bullish Factors Lift Oil Despite Downward Pressure -- Market Talk

7. juuli 2025, 14:45 UTC

Market Talk

Saudi Arabia Not Seeking to Take Oil Market Share -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Alkermes PLC Prognoos

Hinnasiht

By TipRanks

38.65% tõus

12 kuu keskmine prognoos

Keskmine 40 USD  38.65%

Kõrge 46 USD

Madal 30 USD

Põhineb 12 Wall Streeti analüütiku instrumendi Alkermes PLC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

12 ratings

8

Osta

4

Hoia

0

Müü

Tehniline skoor

By Trading Central

27.95 / 30.91Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Strong Bearish Evidence

Pikk perspektiiv

Strong Bullish Evidence

Sentiment

By Acuity

143 / 375 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.